EPAS1 and hepatocellular carcinoma: For example, HIF-2α in clear-cell renal cell carcinoma promotes tumourigenesis17, 57, whereas it suppresses tumourigenesis in hepatocellular carcinoma and non-small cell lung adenocarcinoma20, 21.